Cytokines are key mediators of the development and homeostasis of haematopoietic cells,
critical for host defense, but also for the development of autoimmune and inflammatory …

Numerous chronic inflammatory skin diseases are associated with the release of
proinflammatory cytokines, which act via the intracellular JAK‐STAT pathway. JAK inhibitors …

The US Food and Drug Administration (FDA) has recently added a new 'black box
warning'on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of …

The past decade has witnessed an explosion in trial data on JAK inhibitors (JAKi). These
small molecules target the Janus kinase-signal transducer and activator of transcription (JAK …

Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis.
Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific …

New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–
signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling …

The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1,
JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK …

Objectives To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of
malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and …

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular
signaling pathway is implicated in the pathogenesis of a number of inflammatory …

ABSTRACT Introduction To date, four Janus kinase inhibitors (JAKis) are licensed for the
treatment of rheumatoid arthritis (RA) and/or psoriatic arthritis (PsA) in North America and/or …